NCT05724771View on ClinicalTrials.gov

COACT Study: CGRPmAbs + OnabotulinumtoxinA Assessment of Chronic Migraine Treatments Study

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 26, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

May 31, 2025

Conditions
Chronic Migraine, Headache
Interventions
DRUG

Combination of Botox + CGRPmAb (Fremanezumab 225mg/1.5mL)

OnabotulinumtoxinA + Fremanezumab 225mg/1.5mL

Trial Locations (1)

60657

Chicago Headache Center & Research Institute, Chicago

All Listed Sponsors
lead

Chicago Headache Center & Research Institute

OTHER